VANDA PHARMACEUTICALS INC. Available-for-sale Securities
VANDA PHARMACEUTICALS INC. (VNDA) had Available-for-sale Securities of $100.91 million as of 2016-12-31, per its 10-K filed 2017-02-17.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecurities · last filed 2017-02-17
- 2016-12-31: Available-for-sale Securities $100.91M.
- 2016-09-30: Available-for-sale Securities $109.81M.
- 2016-06-30: Available-for-sale Securities $112.80M.
- 2016-03-31: Available-for-sale Securities $99.59M.
| Period end | Available-for-sale Securities |
|---|---|
| 2016-12-31 | $100.91M 10-K · filed 2017-02-17 |
| 2016-09-30 | $109.81M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $112.80M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $99.59M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $92.34M 10-K · filed 2017-02-17 |
| 2015-09-30 | $97.53M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $98.30M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $101.52M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $68.92M 10-K · filed 2016-02-12 |
| 2014-09-30 | $40.78M 10-Q · filed 2014-10-27 |
| 2014-06-30 | $46.59M 10-Q · filed 2014-08-08 |
| 2014-03-31 | $57.14M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $65.59M 10-K · filed 2015-03-13 |
| 2012-12-31 | $31.63M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |